Predicting survival in cost-effectiveness analyses based on clinical trials

International Journal of Technology Assessment in Health Care

Volumn 19, Issue 3, 2003, Pages 507-512

  Gerdtham, Ulf G ^a   Zethraeus, Niklas ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Confidence intervals; Cost effectiveness analysis; Modeling

Indexed keywords

CLINICAL TRIALS; INCREMENTAL COST-EFFECTIVENESS RATIO (ICER); RANDOMIZED CONTROLLED TRAIL (RCT);

CARDIOLOGY; COST EFFECTIVENESS; MATHEMATICAL MODELS; SENSITIVITY ANALYSIS;

HEALTH CARE;

ENALAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANALYTIC METHOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HUMAN; MODEL; PARAMETER; PREDICTION; RANDOMIZATION; REVIEW; SURVIVAL; ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; MORTALITY; STANDARD; STATISTICAL MODEL; SWEDEN; TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ENALAPRIL; HEART FAILURE, CONGESTIVE; HUMANS; LIKELIHOOD FUNCTIONS; SURVIVAL ANALYSIS; SWEDEN; TIME;

EID: 0141652868     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462303000436     Document Type: Review

References (9)

1. Ekman M, Zethraeus N, Jönsson B. Cost-effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden. Analysis using data from the cardiac insufficiency bisoprolol study II. Pharmacoeconomics 2001;19:1-17.
2. Greene WH. Econometric analysis. New York: Prentice Hall International; 2000.
3. Jönsson B, Cook JR, Pederswen TR. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial. Diabetologia. 1999;42:1293-1301.
4. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996;17:1001-1007.
5. Kiefer NM. Economic duration data and hazard functions. J Econ Lit. 1988;26:646-679.
6. Lancaster T. The econometric analysis of transition data. Cambridge: Cambridge University Press; 1990.
7. Raikou K, Gray A, Briggs A, et al. for the UK prospective diabetes study group. Cost effectiveness analysis of improved blood pressurecontrol in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998;317:720-726.
8. Swedberg K, Kjekshus J, Snapinn S, for the consensus investigators. Long term survival in severe heart failure patients treated with enalapril. Eur Heart J. 1999;20:136-139.
9. The Consensus trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (consensus). N Engl J Med. 1987;316:1429-1435.